Study maps microRNA changes in canine mammary adenocarcinoma

A new Scientific Reports study mapped altered microRNA expression in canine mammary adenocarcinoma and linked those changes to cancer pathways already familiar in human breast oncology, including PI3K/AKT/mTOR, Wnt/β-catenin, and epithelial-mesenchymal transition. The researchers compared mammary tumor tissue from 10 dogs with healthy mammary tissue from 4 controls, using qRT-PCR to profile 84 microRNAs. They found six upregulated microRNAs — including miR-101, miR-106b, miR-143, miR-15a, miR-205, and miR-93 — and four downregulated ones — let-7c, miR-10b, miR-191, and miR-26a — in adenocarcinoma samples. The paper positions these signatures as potential biomarker candidates for diagnosis and, eventually, treatment stratification in canine mammary tumors. (pubmed.ncbi.nlm.nih.gov)

Why it matters: For veterinary professionals, the study adds molecular detail to a disease that remains one of the most common neoplasms in female dogs and a clinically important comparative model for human breast cancer. The findings don’t change case management today, but they reinforce where the field is heading: beyond histopathology alone and toward biomarker-informed oncology, with possible future applications in prognosis, therapeutic targeting, and less invasive testing. That said, the study was small, used pooled samples, and the authors note that pathway predictions relied partly on human-derived databases, so the results are best viewed as hypothesis-generating rather than practice-changing. (nature.com)

What to watch: The next step is validation in larger, clinically annotated cohorts, especially to see whether these microRNA patterns correlate with grade, metastasis, survival, or blood-based biomarker performance. (nature.com)